Evidence map›Paper›PMID 40094223›Full record

ArticleFuture medicinal chemistry2025

Anti-breast cancer potential of thieno-pyrimidine derivatives as VEGFR-2 inhibitors.

Aisha A Alsfouk, Maged Mohammed Saleh Al Ward, Mustafa A Al-Qadhi, Souad A El-Metwally, Reda G Yousef, Eslam B Elkaeed, Dalal Z Husein, Fatma G Amin, Hazem Elkady, Ahmed M Metwaly and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Selected Thieno[2,3-Molecules (Basel, Switzerland) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aisha A AlsfoukDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0000-0003-4497-5013
Maged Mohammed Saleh Al WardMedicinal Chemistry Department, Faculty of Pharmacy, Al Razi University, Sana'a, Yemen.
Mustafa A Al-QadhiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.
Souad A El-MetwallyDepartment of Basic Science, Higher Technological Institute, 10th of Ramadan City, Egypt.
Reda G YousefPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Eslam B ElkaeedDepartment of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
Dalal Z HuseinChemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
Fatma G AminPhysics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Hazem ElkadyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Ahmed M MetwalyPharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Ibrahim H EissaPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThieno-pyrimidine derivatives have emerged as promising candidates for VEGFR-2 inhibition. This study aimed to design, synthesize, and evaluate novel thieno-pyrimidine derivatives for their anti-cancer potential.

methodsA series of thieno-pyrimidine compounds were synthesized and screened for

resultsCompound

conclusionCompound

Indexed as

Antineoplastic AgentsBreast NeoplasmsProtein Kinase InhibitorsPyrimidinesVascular Endothelial Growth Factor Receptor-2ApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsMolecular Docking SimulationMolecular StructureAntineoplastic AgentsKDR protein, humanProtein Kinase InhibitorsPyrimidinesVascular Endothelial Growth Factor Receptor-2apoptosisbreast cancerDFTMD simulationsThieno-pyrimidineVEGFR-2

Identifiers

PMID40094223
PMCPMC12026079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.